Packaging

The Optimµm® technology creates microspheres with high drug loading suitable for taste masking, enteric coatings, and extended release oral applications. The technology is capable of producing single- or double-layer particles in a one manufacturing step, lending to cost-effective creation of palatabl...

The Stratµm™ technology, for injectable delivery, allows for precise control of particle size and composition enabling predictable injectable performance, which is critical for self-administration, extended release, and modified release applications with a narrow therapeutic index. Unlike other encapsu...

The Unisun® technology combines the use of encapsulated or free drug, along with a fast-film forming agent, which allows for low-cost, long-acting intratympanic delivery of a therapeutic. The technology allows for less frequent administrations than current therapies and is capable of sustaining drug le...

Standard Offerings 
• Granulation & Mixing  • Fluid Bed Processing & Drying • Hot Melt Extrusion  • Pan Coating  • Blending  • Tableting  • Multi-layer Tablets  • Capsule Filling  • Oven Drying  • Small-scale GMP Manufacturing ...

Comprehensive R&D Services   • Preformulation • Formulation Development of Solid Dose Tablets (Capsules, Liquids & Solutions) • Pediatric Formulation • Product Design • Formulation Optimization • Sourcing of APIs & Excipients • Analytical Method Development & Validation • ...

Adare’s industry-leading experts possess unparalleled experience in the development of unique dosage forms that provide taste masking, customized release, and patient-centric solutions. Our technology platforms overcome complex formulation challenges to improve the lives of all patients, with expertise in ...

Very few CDMOs can claim Adare's level of experience in mitigating the presence of nitrosamine. We can employ our own-in-house mitigation processes to develop the best long-term control strategies for your product. 

Regain control of your product with NitroCLEARx • Receive real-world mitiga...

Adaptdose™, Adare’s unique commercialized approach to adaptive formulation design, is a highly flexible, multi-delivery platform tool that eliminates the need for post Phase 1 trial reformulations and facilitates the creation of custom oral delivery systems. Adaptdose provides the ability to combine 2-3 ac...

CAT.one SM minimizes the potential for abuse by ensuring that drug products are evaluated for all potential routes of misuse. Adare’s experts integrate abuse-deterrent testing by replicating basic and multi-step methods that an abuser may use to prepare the product for recreational misuse or abuse. Our CAT...

DIFFUTAB® technology is an effective solution for targeted drug delivery through customized and sustained release. The technology assists the development of high-dosage and sustained release products for once-daily administration. A matrix tablet is coated with functional polymers, followed by a blend of h...

Duragran™ allows for more uniformity and precise control of targeted particle sizes while providing production time and cost savings. It eliminates the need for extrusion and spheronization for high API-loaded drug particulates by using fluid bed processing technology that combines the particle sizing and ...

Microcaps® Taste Masking and Modified Release Technology achieves uniform and efficient coating of drug particles by coacervation (phase separation) to build polymeric membranes of varying porosity and thickness. The result is a free-flowing powder containing microencapsulated API (or API substrate) in a w...

In Philadelphia in May on site at CPHI North America we were able to meet with some of our speakers regarding their presentations. In the following interview Srinivasan Shanmugam, Executive Director, Pharmaceutical Sciences, Business Support, and New Technologies at Adare Pharma Solutions discusses his breakfast session. 

Explore Adare's capabilities through our interactive brochure, showcasing our technology-driven CDMO with integrated end-to-end services. With extensive capacity, experience, and a global track record, Adare is your partner for small molecule oral solid dose success.

Throughout CPHI North America 2023, several Breakfast Sessions were held to start the day off right with a complimentary breakfast and a networking and learning session for our attendees. With insightful presentations from industry experts and partners, the CPHI North America Breakfast Sessions had something for everyone looking to fill their brains and their stomachs. 

In pharma, it is essential to identify the right partner to ensure a successful outcome. Time and time again, mistakes have been made in this process, causing clinical studies to fail and for the company to take a heavy hit. Want to avoid this? join our one-hour masterclass where we will devise a checklist for choosing your first CDMO. Discussion Points Thinking ahead before executing – why it is essential to map out what you need to achieve in all departments Why creating a business partnership case to potential CDMOs will determine if they are the right fit for you A checklist of the common pitfalls and how to avoid

Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 

The following session has been SOLD OUT. For any inquiries, please contact a member of staff on the day Kickstart your CPHI North America with a coffee and pastry, connect with your peers, and listen to exclusive content surrounding patient-centric development The challenge of ensuring medication acceptance and adherence is particularly acute in special populations, such as pediatric and geriatric groups. These populations exhibit distinct pharmacokinetic and pharmacodynamic profiles due to their unique age-related physiological and biopharmaceutical characteristics. Consequently, the standard approaches to medication formulation often fall short of addressing their specific needs. This presentation will explore the unique aspects of pediatric and geriatric populations, highlighting the limitations encountered in the design and development of dosage forms tailored for them, and how those challenges are overcome. A significant focus will be placed on the strategies that can be employed to overcome these challenges, with an emphasis on Adare’s platform technologies. Through this discussion, we aim to shed light on the critical factors that must be considered in the development of effective, patient-friendly pharmaceutical formulations for pediatric and geriatric patients.